Michael Patrick Pignone, M.D., M.P.H., of the University of North Carolina, Chapel Hill, and colleagues conducted a randomized clinical in October 2011 in which men underwent a values clarification task and then chose the most important attribute for prostate-specific antigen (PSA) screening. Â...
Analyzing prostate-specific antigen (PSA) velocity and its rate of increase over time may help physicians better assess which patients require biopsy and active treatment and could, according to researchers from Innsbruck, Austria, result in significant healthcare savings. These data were...
Analyzing prostate-specific antigen (PSA) velocity and its rate of increase over time may help physicians better assess which patients require biopsy and active treatment and could, according to researchers from Innsbruck, Austria, result in significant healthcare savings. These data were...
Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer...
Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer...
Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer...
UroToday.com - In the Journal of the National Cancer Institute, Dr. Elizabeth Wever and investigators from Rotterdam report that PSA screening in detecting prostate cancer (CaP) was lower in the United States than in the European Randomized Study of Screening for Prostate Cancer-Rotterdam...
UroToday.com - Detection of PSA with increasing sensitivity may enhance several aspects of disease monitoring. Micro- and nanoelectromechanical systems (MEMS and NEMS) are new devices for detection of infectious agents and disease biomarkers. These systems are of small size and high sensitivity...